Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

In a major step towards a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

Isolating asymptomatic C. diff carriers linked with lower incidence of infection Screening and isolating asymptomatic Clostridium difficile carriers was associated with a reduction in incidence of ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...

Age, fecal calprotectin level, toxin B polymerase chain reaction cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

These toxins damage the lining of the colon and can cause a significant infection. Even a short course of antibiotics may lead to a C. diff infection, especially in people with weakened immune systems ...